NURTEC ODT 4 Dosage And Administration

rimegepant

(

4.1 Dosing Considerations

  • Hepatic impairment:
    The use of NURTEC ODT in patients with severe hepatic impairment should be avoided (see 10.3 Pharmacokinetics). 
  • Renal impairment:
    Use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min) and those undergoing dialysis should be avoided (see 10.3 Pharmacokinetics).

4.2 Recommended Dose and Dosage Adjustment

The recommended dose is 75 mg rimegepant, as needed, once daily.

The maximum dose per day is 75 mg rimegepant. The safety of taking more than 15 doses in a 30-day period has not been established.

Geriatric population:

There is limited experience with rimegepant in patients aged 65 years or older. Clinical trials with rimegepant did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients (n=131 treated with rimegepant). In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. (see 7.1.4 Geriatrics, 10.3 Pharmacokinetics).

Hepatic impairment:

No dosage adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Plasma concentrations of rimegepant were significantly higher in subjects with severe (Child-Pugh C) hepatic impairment. Avoid use of NURTEC ODT in patients with severe hepatic impairment (see 7.1.5 Hepatic Impairment, 10.3 Pharmacokinetics).

Renal impairment:

No dosage adjustment is required in patients with mild, moderate, or severe renal impairment.  NURTEC ODT has not been studied, and therefore should be avoided, in patients with end-stage renal disease (CLcr < 15 mL/min) and in patients on dialysis (see 7.1.6 Renal Impairment, 10.3 Pharmacokinetics).

4.4 Administration

Instruct the patient on the following administration instructions:

  • Use dry hands when opening the blister pack.
  • Peel back the foil covering of one blister and gently remove the orally disintegrating tablet (ODT). Do not push the ODT through the foil.
  • As soon as the blister is opened, remove the ODT and place on the tongue; alternatively, the ODT may be placed under the tongue.
  • The ODT will disintegrate in saliva so that it can be swallowed without additional liquid. NURTEC ODT may be taken with or without food.
  • Take the ODT immediately after opening the blister pack. Do not store the ODT outside the blister pack for future use.
)

Find NURTEC ODT medical information:

Find NURTEC ODT medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NURTEC ODT Quick Finder

Product Monograph
Download Product Monograph

Health Professional Information

4 Dosage And Administration

4.1 Dosing Considerations

  • Hepatic impairment:
    The use of NURTEC ODT in patients with severe hepatic impairment should be avoided (see 10.3 Pharmacokinetics). 
  • Renal impairment:
    Use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min) and those undergoing dialysis should be avoided (see 10.3 Pharmacokinetics).

4.2 Recommended Dose and Dosage Adjustment

The recommended dose is 75 mg rimegepant, as needed, once daily.

The maximum dose per day is 75 mg rimegepant. The safety of taking more than 15 doses in a 30-day period has not been established.

Geriatric population:

There is limited experience with rimegepant in patients aged 65 years or older. Clinical trials with rimegepant did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients (n=131 treated with rimegepant). In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. (see 7.1.4 Geriatrics, 10.3 Pharmacokinetics).

Hepatic impairment:

No dosage adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Plasma concentrations of rimegepant were significantly higher in subjects with severe (Child-Pugh C) hepatic impairment. Avoid use of NURTEC ODT in patients with severe hepatic impairment (see 7.1.5 Hepatic Impairment, 10.3 Pharmacokinetics).

Renal impairment:

No dosage adjustment is required in patients with mild, moderate, or severe renal impairment.  NURTEC ODT has not been studied, and therefore should be avoided, in patients with end-stage renal disease (CLcr < 15 mL/min) and in patients on dialysis (see 7.1.6 Renal Impairment, 10.3 Pharmacokinetics).

4.4 Administration

Instruct the patient on the following administration instructions:

  • Use dry hands when opening the blister pack.
  • Peel back the foil covering of one blister and gently remove the orally disintegrating tablet (ODT). Do not push the ODT through the foil.
  • As soon as the blister is opened, remove the ODT and place on the tongue; alternatively, the ODT may be placed under the tongue.
  • The ODT will disintegrate in saliva so that it can be swallowed without additional liquid. NURTEC ODT may be taken with or without food.
  • Take the ODT immediately after opening the blister pack. Do not store the ODT outside the blister pack for future use.

Resources

Didn’t find what you were looking for? 

Contact us

Call 1-800-463-6001*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

Canada Vigilance Program 

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect